Recognising the firm both as a whole and for individual achievement, Wrays is honoured to receive two ACQ Law Awards for 2013. Principal at Wrays, Peter Caporn, has been named as a Leading Patent & Trade Mark Attorney of the Year. In addition, Wrays has also won Patent & Trade Mark Firm of the Year. ACQ’s approach is: “…designed to …
Former Football Player Takes Nike to Court Over Nickname Trade mark
Former professional American football player Shawne Merriman has recently commenced litigation in the US against global sporting goods giant Nike, alleging that the sports apparel and footwear company has infringed a trade mark that he owns for the term “Lights Out.”
Neglect Engagement at your peril…
Jo Woodfield, Principal, and EGM Brand, Culture and Research services, WRAYS Employee engagement is simply a by-product of clearly-led, well-performing and well-managed organisation however any slowdown or period of recovery can easily blindside leadership. A fall in demand, widespread uncertainty, lower consumer confidence all drive organisations to re-evaluate their cost-base, consolidate, reposition and often there’s that overarching need to do more with less – so no surprise there’s an obvious tension between cost-cutting and …
Talking Productivity – Labour and Leaders
Jo Woodfield, Principal, Wrays Australia is in grip of a productivity crisis. Our focus deflected during the commodity boom (and quite spectacularly so) from what has been and still is, glaring lack-lustre performance. Fast becoming uncompetitive in global markets, Australia’s high labour costs continue to debilitate many of our sectors. GM Holden is case in point, faced with manufacturing vehicle …
Employer Branding Framework
Wrays model helps to guide and monitor Employer brand, EVP development, strategy, communications and ultimately optimisation. Essentially a strategic, inside-out process involving your team and deriving real value from developing and internalising the EVP. For more information on how this framework is executed, perhaps even some fresh thinking in relation to your existing Employer Branding email Jo Woodfield Principal Wrays or one of the team here. EMPLOYER BRAND FRAMEWORK
The High Court of Australia confirms that claims to methods of medical treatment are patentable in Australia
Authors: Gary Cox, Craig Humphris and Donna Meredith In the decision of Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50, the High Court of Australia, Australia’s supreme court, confirmed that methods of medical treatment are a “manner of manufacture” and therefore represent a patentable invention in Australia. Although Australia’s Patent Office (IP Australia) and the Australian …
iCeutica recieves US FDA approval
Wrays would like to congratulate its client, iCeutica, on its success receiving US FDA approval for the pain drug, ZORVOLEX™ (diclofenac), which uses iCeutica’s SoluMatrix Fine Particle Technology™. Read more here
Innovation critical to Australia’s competitiveness
Dr Gillian Kaggwa, Technical Assistant, Wrays Perth Peter Caporn, Principal, Wrays Perth Innovation plays a critical role in strengthening Australia’s economy and global competiveness, as identified in a recent overview of Australia’s economy by Michael Enright and Richard Petty titled Australia’s Competitiveness: From Lucky Country to Competitive Country.1 Innovation facilitates growth in productivity, market diversity, exports and employment and, as …
Resources sector missing out due to poor IP management
Albert Ferraloro, Principal Wrays Management and Strategic services A review of patent filing statistics for the petroleum sector (Thomson Reuters: 2012 State of Innovation Report) suggests many Australian resources companies are lagging behind their international counterparts when it comes to formally protecting their innovations. With the increasing realisation that IP assets can represent a significant proportion of the capital value of …
US Supreme Court rules isolated DNA lacks patent eligibility
On 13 June 2013, the United States Supreme Court ruled in Association for Molecular Pathology v. Myriad Genetics (“Myriad”) that: For the reasons that follow, we hold that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that cDNA is patent eligible because it is not naturally occurring. …